Publications by authors named "Giada Rizzi"

Claim this Profile
P
Phase 3 Study of Palonosetron IV Infusion Vs. IV Bolus for Chemotherapy-Induced Nausea and Vomiting Prophylaxis After Highly Emetogenic Chemotherapy.
Meinolf Karthaus, Daniel Voisin, Giada Rizzi, Tudor Ciuleanu

J Pain Symptom Manage· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Lee Schwartzberg, Rudolph Navari, Rebecca Clark-Snow, Ekaterine Arkania, Irena Radyukova, Giada Rizzi

Oncologist· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Galina Kurteva, Nataliya Chilingirova, Giada Rizzi, Tatiana Caccia, Valentino Stella

Eur J Pharm Sci· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
Lee Schwartzberg, Meinolf Karthaus, Giorgia Rossi, Giada Rizzi, Maria E Borroni

Cancer Med· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
Snežana M Bošnjak, Ljiljana Stamatovic, Maria Elisa Borroni, Giada Rizzi, Karin Jordan

Int J Gynecol Cancer· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
Hope S Rugo, Giorgia Rossi, Giada Rizzi, Matti Aapro

Breast· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
Matti Aapro, Meinolf Karthaus, Lee Schwartzberg, Igor Bondarenko, Tomasz Sarosiek, Giada Rizzi

Support Care Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients.
Matti Aapro, Karin Jordan, Richard J Gralla, Giada Rizzi, Giorgia Rossi

J Geriatr Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.
Karin Jordan, Richard Gralla, Giada Rizzi, Kimia Kashef

Support Care Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Matti Aapro, Paul J Hesketh, Karin Jordan, Richard J Gralla, Giorgia Rossi, Giada Rizzi

Oncologist· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
Meinolf Karthaus, Csőszi Tibor, Vito Lorusso, Rajender Singh-Arora, Alexander Filippov, Giada Rizzi

Support Care Cancer· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis combining 2 previously reported trials on respiratory distress syndrome in neonates.
Stephen Senn, Marco Costantini, Giada Rizzi

Pediatrics· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis